Taken together, these observations suggest that ibrutinib inhibits Aβ-activated EGFR (off-target of ibrutinib), which suppresses GSK-3β phosphorylation at Y216 and subsequently attenuates tau hyperphosphorylation in a mouse model of AD. Here, EGFR is linked to Alzheimer disease.